Infections and cancer
PRINCIPAL INVESTIGATORS
- Francesc Xavier Bosch José
- Maria Brotons Agulló
- Laia-Valeria Bruni Coccoz
- Delphine Casabonne
- Laura Costas Caudet
- Mireia Díaz Sanchís
- Raquel Ibáñez Pérez
- Miguel Angel Pavon Ribas
- Sònia Paytubi Casabona
- Claudia Robles Hellin
CLINICAL RESEARCHERS
- Samuel Perez Carton
POSTDOCTORAL RESEARCHERS
- Ginesa Albero Abril
- Marta Lopez Querol
PREDOCTORAL RESEARCHERS
- Alvaro De Andres Pablo
- Irene Onieva Hernandez
- Beatriz Serrano Carro
SCIENTIFIC SUPPORT
- Alicia Ares Vilar
- Alexandre Armillas Montornes
- Yolanda Benavente Moreno
- Ainhoa Botella Cayuelas
- Vanesa Camon Melguizo
- Omar Clavero Carletti
- Carlos Javier Dommar D Lima
- Ana Esteban Miró
- Yolanda Florencia Melgarejo
- Jon Frias Gomez
- David Gómez Guillén
- Victoria Lopez Codony
- Alexandra Montoliu Gimenez
- Francisca Morey Cortes
- Claudia Pavon Diaz
- Beatriz Thais Pelegrina Sanchez-Dehesa
- Gonzalo Peon Pena
- Paula Àngela Peremiquel Trillas
- Beatriz Quirós Blasco
- Valentina Rangel Sarmiento
- Esther Roura Fornells
- Gabriela Tejada Panduro
- Sara Tous Belmonte
- Marleny Vergara Muñoz
MANAGEMENT SUPPORT
- Maria Gema Carretero Garcia
Arnau Guasch Girbau - German Lopez Martos
- Mireia Montserrat Moreno
- Jesus Muñoz Villanueva
- Natividad Paton Morales
- Frederic Rodilla Pamies
- Olga Romero Clara
- Francisco Javier Ruiz Carrasco
- Elena Carmen Ruiz Puig
- Gaetano Vaggione
Cancer
EPIBELL
Scientific production
28
PAPERS
Average IF: 5,33
5
LED PAPERS
Average IF: 6,26
6 PUBLICATIONS IN FIRST DECILE
17 PUBLICATIONS IN FIRST QUARTILE
21 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Watson Jones,D;Changalucha,J;Maxwell,C;Whitworth,H;Mutani,P;Kemp,TJ;Kamala,B et al, Durability of immunogenicity at 5 years after a single dose of human papillomavirus vaccine compared with two doses in Tanzanian girls aged 9-14 years: results of the long-term extension of the DoRIS randomised trial., Lancet Glob Health, 2025;13(2):319-328, doi:10.1016/S2214-109X(24)00477-7
- Ebrahimi,E;Sangphukieo,A;Park,HA;Gaborieau,V;Ferreiro Iglesias,A;Diergaarde,B;Ahrens,W et al, Cross-ancestral GWAS identifies 29 variants across head and neck cancer subsites, Nat. Commun., 2025;16(1):8787-8787, doi:10.1038/s41467-025-63842-z
- Alemany,L;Felsher,M;Giuliano,AR;Waterboer,T;Mirghani,H;Mehanna,H;Roberts,C et al, Oral human papillomavirus (HPV) prevalence and genotyping among healthy adult populations in the United States and Europe: results from the PROGRESS (PRevalence of Oral hpv infection, a Global aSSessment) study, EClinicalMedicine, 2025;79103018-103018, doi:10.1016/j.eclinm.2024.103018
- Almanza Aguilera,E;Guananga Alvarez,D;Benavente,Y;Nieters,A;Besson,C;Saberi Hosnijeh,F;Kyro,C et al, Intake of total, classes, and subclasses of (poly)phenols and risk of lymphoid neoplasms: a prospective analysis in the EPIC cohort, Br J Cancer, 2025;133(12):1864-1871, doi:10.1038/s41416-025-03228-6
- Hermosa,S;Benavente,Y;Cabezudo,E;Sainz,J;Farràs,M;Alemany,L;Birmann,BM et al, Serum lipid levels and risk of lymphoid malignancies in the UK Biobank study., Br J Cancer, 2025;133(11):1686-1694, doi:10.1038/s41416-025-03196-x
Research highlights
PROJECTS
1 Granted competitive project
23 Ongoing competitive projects
3 Ongoing clinical trials
NETWORKS
AGAUR SGR GRC
CIBERESP
Selected projects
- GAIN-EC – Crida Repte CIMTI 2023. FUNDACION LEITAT. Budget: 444.120,7€. 2023-2025. PI: LAURA COSTAS CAUDET.
- 101075314. PERCH: PartnERship to Contrast HPV. COMISSIÓ EUROPEA. Budget: 409.468,03€. 2022-2025. PI: MARIA BROTONS AGULLÓ.
- INV-074218. HPV vaccination and Infectivity Reduction in HPV-positive women (RIFT-TZ). BILL & MELINDA GATES FOUNDATION. Budget: 275.855,93€. 2024-2026. PI: MIGUEL ANGEL PAVON RIBAS.
- 101159996-1. IMPPROVE-HPV: Understanding vaccination hesitancy and evaluating single dose and gender-neutral vaccination for improving uptake of HPV vaccines in West and East Africa. COMISSIÓ EUROPEA. Budget: 251.775,74€. 2024-2028. PI: MIGUEL ANGEL PAVON RIBAS.
- V503-049. ENSAYO CLÍNICO EN FASE 3, INTERNACIONAL, MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO PARA ESTUDIAR LA EFICACIA, LA INMUNOGENICIDAD Y LA SEGURIDAD DE LA VACUNA 9VVPH, UNA VACUNA POLIVALENTE DE PARTÍCULAS VIROIDES L1, EN LA PREVENCIÓN DE LA INFECCIÓN BUCAL PERSISTENTE POR LOS TIPOS 16, 18, 31, 33, 45, 52 O 58 DEL VPH EN VARONES ADULTOS DE 20 A 45 AÑOS DE EDAD.. MERCK SHARP & DOHME ESPAÑA S.A.. Budget: 224.455€. 2020- . PI: MARÍA EULALIA ALEMANY VILCHES.